Nebulisable liposomes – Method for the pulmonary delivery of agents
The treatment of lung and respiratory diseases, such as asthma and Chronic Obstructive Pulmonary Disease (COPD), pneumonia and pulmonary hypertension, is carried out by means of agents with a long biological half-life. Liposomes are favoured that remain as stable as possible during nebulisation and that achieve a delayed release of the agent with as few side-effects as possible.
The liposome formulations at hand fulfil these requirements of the delivery of pharmaceutical agents to the lung in an outstanding manner. They are characterised by a good tolerance, because they are composed out of the body's own substances that are found naturally in the lung. The composition of liposomes is selected in such a way that the agents packed therein are released selectively and over a specific period of time, in a controlled manner.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Microscopic basis of a new form of quantum magnetism
Not all magnets are the same. When we think of magnetism, we often think of magnets that stick to a refrigerator’s door. For these types of magnets, the electronic interactions…
An epigenome editing toolkit to dissect the mechanisms of gene regulation
A study from the Hackett group at EMBL Rome led to the development of a powerful epigenetic editing technology, which unlocks the ability to precisely program chromatin modifications. Understanding how…
NASA selects UF mission to better track the Earth’s water and ice
NASA has selected a team of University of Florida aerospace engineers to pursue a groundbreaking $12 million mission aimed at improving the way we track changes in Earth’s structures, such…
